Rxrx stock forecast.
What this means: Recursion Pharmaceuticals Inc Cl (RXRX) gets an Overall Rank of 60, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value.
Analyst projections state that RXRX is forecast to be at a low of $9.00 and a high of $35.00. In order for the stock price to hit the forecast high, the stock would need to plunge -435.99% from its current level, while the stock would need to crash -37.83% from its current level to reach the projected low.60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share.Track Recursion Pharmaceuticals Inc - Ordinary Shares - Class A (RXRX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsStock Price Forecast. The 7 analysts offering 12-month price forecasts for Recursion Pharmaceuticals Inc have a median target of 14.00, with a high estimate of 35.00 and a low estimate of 9.00 ... RXRX Stock Performance on July 28, 2023: Decrease in Price and Analyst Forecasts. RXRX stock performance on July 28, 2023, showed a decrease from the previous price. The 12-month price forecasts for Recursion Pharmaceuticals Inc provided by 8 analysts had a median target of 12.50, with a high estimate of 35.00 and a low estimate of 9.00.
Recursion Pharma may be a biotech stock, but it scored a $50 million investment from Nvidia to fund its AI technology in mid-July - making NVDA a significant stakeholder in RXRX. The partnership ...
8 авг. 2023 г. ... RXRX+0.08 (+1.17%) After Hours. Share Share Article via ... Global Business and Financial News, Stock Quotes, and Market Data and Analysis.
2 days ago · RXRX has an Altman Z-Score of 1.55 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy. Detailed statistics for Recursion Pharmaceuticals, Inc. (RXRX) stock, including valuation metrics, financial numbers, share information and more. Great weather can motivate you to get out of the house, while inclement weather can make you feel lethargic. When the weather’s great we want to be outside enjoying it. For the best regional weather forecasts check out AccuWeather.Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has been making great progress lately in being able to advance its pipeline. That's because it has been advancing two clinical candidates in phase 2 ...Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...After announcing that it would get a $50 million investment from NVIDIA ( NVDA 0.67%) on July 12, Recursion Pharmaceuticals ( RXRX 0.43%) saw its stock blast off, rising 87% over the following two ...
May 18, 2023 · "Over the next 10 years, AI could increase productivity by 1.5% per year. And that could increase S&P500 profits by 30% or more over the next decade," Goldman Sach's senior strategist Ben Snider ...
RXRX Stock Performance on July 28, 2023: Decrease in Price and Analyst Forecasts. RXRX stock performance on July 28, 2023, showed a decrease from the previous price. The 12-month price forecasts for Recursion Pharmaceuticals Inc provided by 8 analysts had a median target of 12.50, with a high estimate of 35.00 and a low estimate of 9.00.
(See RXRX stock forecast) Roblox Corporation ( RBLX ) The AI trend has driven 2023’s bullish market sentiment, but one previously anticipated trend has failed to materialize.Recursion Pharmaceuticals, Inc. (RXRX) : Free Stock Analysis Report. Omega Therapeutics, Inc. (OMGA) : Free Stock Analysis Report ... according to the …Recursion’s Q1 2023 earnings show revenue as small but growing fast, growing from $5.3 million to $12.1 million year on year. With a net-loss of $65 million, Recursion is still an unprofitable ...First on the list of Cathie Wood stocks is Archer Aviation (NYSE: ACHR ), which is swiftly carving out its name as a juggernaut in the realm of flying cars. Its stock has been on fire this year ...Find the latest GoodRx Holdings, Inc. (GDRX) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Performance Outlook. Short Term. 2W - 6W ...
Analyst Price Forecast Suggests 117.07% Upside As of July 6, 2023, the average one-year price target for Recursion Pharmaceuticals Inc - is 14.72. The forecasts range from a low of 8.08 to a high ...For a biotech like Recursion Pharmaceuticals (RXRX 0.43%) that aims to use artificial intelligence (AI) and petabytes of data as tools for drug discovery and …Find the latest Recursion Pharmaceuticals, Inc. (RXRX) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and …Should You Buy or Sell Recursion Pharmaceuticals Stock? Get The Latest RXRX Stock Analysis, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.Cathie Wood’s ARK Investment bought 1.89M shares of Recursion Pharmaceuticals November 27, 2023TipRanks. Analysts Offer Insights on Healthcare Companies: Recursion Pharmaceuticals (RXRX ...
Sep 11, 2023 · Recursion Pharmaceuticals (RXRX 7.88%) is a biotech that's riding a hype wave unlike any other. By staking its fame and investors' cash on its artificial intelligence (AI) platform for drug ... Dec 4, 2023 · The company, currently valued at $1.60B, closed the last trade at $7.39 per share which meant it gained $0.54 on the day or 7.88% during that session. The RXRX stock price is -126.66% off its 52-week high price of $16.75 and 38.57% above the 52-week low of $4.54. If we look at the company’s 10-day average daily trading volume, we find that it ...
4.31%. €8.59M. RXRX | Complete Recursion Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Recursion Pharmaceuticals, Inc. (RXRX) share price prediction for 2023, 2024, 2025, 2026 and 2027. RXRX one year forecast. Recursion Pharmaceuticals stock monthly and ...According to the current price, Recursion Pharmaceuticals, is 42.39% away from the 52-week high. What are analysts forecasts for Recursion Pharmaceuticals, stock? The 21 analysts offering price ...Jul 6, 2023 · Analyst Price Forecast Suggests 117.07% Upside As of July 6, 2023, the average one-year price target for Recursion Pharmaceuticals Inc - is 14.72. The forecasts range from a low of 8.08 to a high ... Sep 12, 2023 · (See RXRX stock forecast) Roblox Corporation . The AI trend has driven 2023’s bullish market sentiment, but one previously anticipated trend has failed to materialize. Not long ago, all the talk ... "Over the next 10 years, AI could increase productivity by 1.5% per year. And that could increase S&P500 profits by 30% or more over the next decade," Goldman Sach's senior strategist Ben Snider ...NSD:RXRX Detailed Stock Analysis, Stock Price Forecast, Analyst Ratings, Financial Analysis, Stock News & Historic QuotesFind the latest Recursion Pharmaceuticals, Inc. RXRX analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range.On Monday, RXRX stock opened at $9.12. The company’s one-year low is at $4.54 while its one-year high stands at $16.75 – indicating potential volatility in its trading range in the past year. Recursion Pharmaceuticals has a market capitalization value of $1.97 billion along with a PE ratio of -6.61 and a beta coefficient of -0.05 ...He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis ...
The average one-year price target for Recursion Pharmaceuticals Inc - ( NASDAQ:RXRX) has been revised to 17.17 / share. This is an increase of 7.12% from the prior estimate of 16.03 dated August ...
Find the latest Recursion Pharmaceuticals, Inc. RXRX analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range. investment rating ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shareholders will have a reason to smile today, with the analysts making substantial upgrades to next year's forecasts.The consensus statutory numbers ...Forecast for Fri 01 Sep 2023 price 7.05 RECURSION PHARMACEUTICALS INC stock price forecast for further price development up to 32.48% (time horizon: 1 day) and price target of 7.01 USD. Short-term (time horizon: 2 weeks) RECURSION PHARMACEUTICALS INC share price prediction for 2023-09-01 with daily closed price …If you bought Keurig K-Cup coffee pods at any point between June 2016 and August 2022, you might be entitled to some cash from a court settlement.What are analysts forecasts for Recursion Pharmaceuticals, stock? The 21 analysts offering price forecasts for Recursion Pharmaceuticals, have a median target of 14.62, with a high estimate of 33. ...Wall Street Stock Market & Finance report, prediction for the future: You'll find the Xerox Holdings share forecasts, stock quote and buy / sell signals below. According to present data Xerox Holdings's XRX shares and potentially its market environment have been in bearish cycle last 12 months (if exists).Recursion Pharmaceuticals Inc. research and ratings by Barron's. View RXRX revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.According to the issued ratings of 2 analysts in the last year, the consensus rating for Xerox stock is Sell based on the current 2 sell ratings for XRX. The average twelve-month price prediction for Xerox is $14.67 with a high price target of $17.00 and a low price target of $12.00. Learn more on XRX's analyst rating history.Wall Street is abuzz with the news of Nvidia’s $50 million investment in Recursion Pharmaceuticals (NASDAQ:RXRX). The biotech company’s stock surged over 120% following the announcement ...Zillow is worth $8.3 billion right now, so if it reaches its 2025 sales estimate and continues to grow thereafter, it should breeze past a $10 billion valuation by 2030. 2. Duolingo: Potential ...Recursion Pharma may be a biotech stock, but it scored a $50 million investment from Nvidia to fund its AI technology in mid-July - making NVDA a significant stakeholder in RXRX. The partnership ...
Find the latest Recursion Pharmaceuticals, Inc. RXRX analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range.Vanguard Group Inc. now owns 8,380,986 shares of the company’s stock worth $89,174,000 after purchasing an additional 1,393,519 shares in the last quarter. 57.82% of the stock is owned by ...The company, currently valued at $1.60B, closed the last trade at $7.39 per share which meant it gained $0.54 on the day or 7.88% during that session. The RXRX stock price is -126.66% off its 52-week high price of $16.75 and 38.57% above the 52-week low of $4.54. If we look at the company’s 10-day average daily trading volume, we find that it ...Jul 28, 2023 · RXRX Stock Performance on July 28, 2023: Decrease in Price and Analyst Forecasts. RXRX stock performance on July 28, 2023, showed a decrease from the previous price. The 12-month price forecasts for Recursion Pharmaceuticals Inc provided by 8 analysts had a median target of 12.50, with a high estimate of 35.00 and a low estimate of 9.00. Instagram:https://instagram. black model s teslawhat does george soros ownus steel stocksbenzinga pro reviews Jul 28, 2023 · RXRX Stock Performance on July 28, 2023: Decrease in Price and Analyst Forecasts. RXRX stock performance on July 28, 2023, showed a decrease from the previous price. The 12-month price forecasts for Recursion Pharmaceuticals Inc provided by 8 analysts had a median target of 12.50, with a high estimate of 35.00 and a low estimate of 9.00. best 3d printer under 200option trading class Recursion Pharmaceuticals Inc. research and ratings by Barron's. View RXRX revenue estimates and earnings estimates, as well as in-depth analyst breakdowns. state farm insurance for motorcycle In particular, both Ginkgo Bioworks (NYSE: DNA) and Recursion Pharmaceuticals (NASDAQ: RXRX) are already implementing AI, and in the long term, it could be a crucial factor in their success.In this article, we answer “what is sales forecasting?” by breaking down its objectives, owners, methods, and best practices. Sales | What is REVIEWED BY: Jess Pingrey Jess served on the founding team of a successful B2B startup and has use...